Activity and Toxicity of Oxaliplatin Plus Raltitrexed in 5-Fluorouracil Refractory Metastatic Colorectal Adeno-Carcinoma

Anticancer Research

Volumn 24, Issue 2 C, 2004, Pages 1139-1142

  Laudani, Agata ^a   Gebbia, Vittorio ^b,d   Leonardi, Vita ^a   Savio, Giuseppina ^a   Borsellino, Nicola ^c   Cusimano, Maria Pia ^a   Calabria, Caterina ^a   Stefano, Rosaria ^a   Agostara, Biagio ^a  

^a Ospedale Oncologico M Ascoli   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c Buccheri La Ferla Fatebenefratelli Hospital   (Italy)

^d Divisione di Oncologia Medica   (Italy)

Author keywords

Colorectal cancer; Metastases; Oxaliplatin; Raltitrexed

Indexed keywords

DEXAMETHASONE; FLUOROURACIL; OXALIPLATIN; RALTITREXED; SEROTONIN 3 ANTAGONIST;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BLOOD TRANSFUSION; CANCER INHIBITION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; HYPOTENSION; LEUKOPENIA; MALE; METASTASIS; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; PAIN; PARESTHESIA; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; QUINAZOLINES; THIOPHENES;

EID: 2442604628     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Landis SH, Taylor M, Bolden S and Wingo PA: Cancer statistics. CA Cancer J Clin 48: 6-29, 1998.
2. Meta-Analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 6: 301-308, 1998.
3. Bertino GR: Chemotherapy of colorectal cancer: history and new themes. Semin Oncol 24 (Suppl. 18): S18-37, 1997.
4. Saltz L, Cox JV, Blanke C et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914, 2000.
5. Douillard JV, Cunningham D, Roth A et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomised trial. Lancet 355: 1041-1047, 2000.
6. De Gramont A, Figer A, Seymour M et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
7. Giacchetti S, Zidani R, Perpoint B et al:. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first line treatment of metastatic colorectal cancer. J Clin Oncol 18: 136-147, 2000.
8. Scheithauser W, Kornek GV, Ulrich-Pur V et al: Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a phase I-II trial. Cancer 91: 1264-71, 2001.
9. Scheithauer W, Kornek GV, Schuell B et al: Second-line treatment with oxaliplatin plus raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin based chemotherapy. Ann Oncol 12: 709-714, 2001.
10. Cascinu S, Graziano F, Ferraù F et al: Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas. Ann Oncol 13: 716-720, 2002.
11. Seitz JF, Bennouna J, Paillot B et al: Multicenter non randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients. Annals of Oncology 13: 1072-1079, 2002.
12. Neri B, Doni L, Fulignati F et al: Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multicentric phase II trial. Anti-Cancer Drugs 13: 719-724, 2002.
13. Cunningham D, Zalcberg JR, Rath U et al: Tomudex (ZD1694): results of a randomized trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The Tomudex Colorectal Cancer Study Group. Eur J Cancer 31A: 1945-1954, 1995.
14. Harper P: Advanced colorectal cancer: results from the latest raltitrexed (tomudex) comparative study Abstract Proc Am Soc Clin Oncol 16: 228a, 1997.
15. Pazdur R and Vincent M: Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5FU+LV) in patients with advanced colorectal cancer: results of a randomized, multicenter, North American trial. Proc Am Soc Clin Oncol 16: 228a, 1997.
16. Cvitkovic E and Bekkarda M: Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol 26: 647-662, 1999.
17. Fizazi K, Ducreux M, Ruffie P et al: Phase I, dose finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer. J Clin Oncol 18: 2293-2300, 2000.
18. Douillard J, Michel P, Gamelin E et al: Raltitrexed (Tomudex) plus oxaliplatin. An active combination for first-line chemotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 19: 250a, 2000.
19. Comella P, De Vita F, De Lucia L, Casaretti R, Avallone A, Orditura M, Rivellini F, Palmeri S, Catalano G and Comella G: Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma. Southern Italy Cooperative Oncology Group. Ann Oncol 11: 461-468, 2000.
20. Martoni A, Mini E, Pinto C, Gentile AL, Nobili S, Dentico P, Marino A, Scicolone S, Angelelli B and Mazzei T: Oxaliplatin plus raltitrexed in the treatment of patients with advanced colorectal cancer: a phase II study. Anticancer Res 23: 687-691, 2003.
21. Comella P, Casaretti R, Crucitta E, De Vita F, Palmeri S, Avallone A, Orditura M, De Lucia L, Del Prete S, Catalano G, Lorusso V and Comella G: Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients. Br J Cancer 86: 1871-1875, 2002.
22. Volk J, Reinke F, van Kuilenburg AB, van Gennip AH, Schlichting C, Ganser A and Schoffski P: Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer. Ann Oncol 12: 569-571, 2001.